Page 114 - CIBERESP-2015-eng

Research groups
Group 34
Programme: Epidemiology and Control of Chronic Diseases Lead Researcher: Sánchez Pérez, María José
Group Members
STAFF MEMBERS: Molina Portillo, Elena | Salamanca Fernández, Elena.
ASSOCIATED MEMBERS: Espín Balbino, Jaime | García Gutiérrez, José Francisco | Martínez García, Carmen
| Sánchez-Cantalejo Ramírez, Emilio.
Main lines of research
The Granada Cancer Registry (GCR), since its startup in 1985, has developed research projects produced by the GCR itself or in collaboration with other national or international institutions, along four main research lines:
• Descriptive epidemiology of cancer:
Temporal trends of cancer incidence in Granada for adults, children and adolescents; Survival of cancer in Granada; Estimates of cancer incidence and prev- alence in Andalusia and Spain; Rare malignant tum- ors (RDR Spain): definition, incidence and survival; Risk of second primary multiple tumors.
• Risk factors for cancer and other chronic diseases, especially in the Framework of the EPIC project (Eu- ropean Prospective Investigation into Cancer and Nutrition).
Studies on the association between lifestyle factors, diet and other environmental factors with risk of cancer and other chronic diseases (diabetes, cardio-
vascular diseases,...); Studies on the association be- tween biomarkers of exposure (antioxidants, inflam- mation, oxidative stress, etc.) with risk of cancer and other chronic diseases; Studies on gen*environment and gen*gen interactions and their association with risk of cancer and other chronic diseases.
• Health care and outcomes assessment in cancer patients.
Survival and patterns of care in cancer and variabil- ity in clinical practice (diagnostic methods, stage, treatment, tumor markers, second primary cancers, recurrences): differences between countries and geographical areas (EUROCARE, CONCORD and EMPARO-CU projects); Surveillance and control of rare tumors in Spain and Europe (EUROCARE pro- ject).
• Health technologies and drugs economic evalua- tion.
-Pricing policies and reimbursement of drugs.
114 I Annual report 2015 I CIBERESP